[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.196.37. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1979

Somatomedin and Growth Hormone StudiesIn Pediatric Renal Allograft Recipients Who Receive Daily Prednisone

Author Affiliations

From the Department of Pediatrics (Drs Pennisi, Costin, Malekzadeh, Uittenbogaart, Ettenger, and Fine), University of Southern California School of Medicine, Los Angeles; the Dialysis and Transplant Program (Drs Pennisi, Malekzadeh, Uittenbogaart, Ettenger, and Fine) and the Endocrinology Metabolism Division (Dr Costin), Childrens Hospital of Los Angeles; and Northwestern University School of Medicine (Dr Phillips), Chicago.

Am J Dis Child. 1979;133(9):950-954. doi:10.1001/archpedi.1979.02130090078016
Abstract

• Plasma somatomedin (SM) activity and growth hormone (GH) concentration were measured in ten growth-retarded, well-nourished pediatric renal allograft recipients who received daily prednisone therapy. The SM activity ranged from 0.21 to 1.22 μ/mL, and it was subnormal in three patients. A significant correlation was found between SM activity and creatinine clearance. Serial SM levels were determined during a 24-hour period in five patients; SM activity decreased at six and 12 hours and returned to normal values by 24 hours. The 24-hour plasma GH concentrations ranged from 1.5 to 7.6 mg/mL. Peak GH concentrations ranged from 2.1 to 14.2 ng/mL after insulininduced hypoglycemia and from 1.8 to 24.6 ng/mL after oral glucose loading. Sleeping GH peaks were absent in two patients. These results suggest that growth failure in renal allograft recipients who receive daily prednisone may result from (1) partial GH deficiency, (2) reduced SM levels owing to diminished allograft function, and (3) daily transient decrease in plasma SM levels after prednisone administration.

(Am J Dis Child 133:950-954, 1979)

×